Accessibility Menu
Skinvisible logo

Skinvisible(OTC) SKVI

Current Price$0.20
Market Cap$1.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-100%
5 Year+43%
1 Year-12%
1 Month-6%
Skinvisible last closing stock price
MetricPriceDate
Last closeUSD 0.202026-07-24
Skinvisible stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.5%USD 0.202026-07-17
1 month-5.93%USD 0.212026-06-11
3 month-16.67%USD 0.242026-04-24
Year to date-13.27%USD 0.232025-12-31
1 year-12.2%USD 0.232025-07-21
3 year+102.02%USD 0.102023-07-25
5 year+42.86%USD 0.142021-07-22
Since inception-99.73%USD 75.001999-01-07

Skinvisible Financials at a Glance

Market Cap

$1.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$20.00K

Net Income (TTM)

-$1.05M

EPS (TTM)

-$0.19

P/E Ratio

-1.03

Dividend

$0.00

Beta (Volatility)

-0.28 (Low)

Price

$0.20

Volume

1

Open

$0.20

Previous Close

$0.20

Daily Range

$0.20 - $0.20

52-Week Range

$0.08 - $0.90

Estimated Earnings Date

May 10, 2023

SKVI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Skinvisible

Skinvisible develops and licenses skin delivery technologies for medicines and skincare. Its products help keep active ingredients on the skin longer. These solutions support pharmaceutical companies and consumers needing effective topical treatments.

Products and Services

  • Invisicare Delivery System: Patented technology for longer-lasting topical and transdermal products; used by pharmaceutical and skincare companies and represents the company's core revenue source.
  • Skinbrella: Sunless tanning and sunscreen products for consumers seeking skin protection and cosmetic benefits.
  • DermSafe: Hand sanitizer licensed to Ovation Science, targeting hygiene and infection control markets.
  • QRX003: Treatment for Netherton Syndrome, licensed to Quoin Pharmaceuticals, serving rare disease patients.
  • Formulation Services: Reformulates off-patent drugs for pharmaceutical clients, extending product life cycles.

Growth and Expansion

  • Licensed QRX003 to Quoin Pharmaceuticals pursuant to a 2019 exclusive license agreement, with clinical development updates announced in 2022 for rare skin disease treatment.
  • Signed global rights deal with Ovation Science in September 2025 for cannabinoid-based products.
  • Filed patents in 2024 for obesity and glucose-control transdermal therapies.
  • Expanded clinical trials for QRX003 internationally by 2025, including additional sites in the UK and Saudi Arabia, and submitted for regulatory approval in Japan.
  • Focused on strategic partnerships to enter new therapeutic areas since 2024.

What Makes Skinvisible Stand Out

Skinvisible’s patented Invisicare system helps active ingredients stay on the skin longer, improving product effectiveness. The company relies on licensing and partnerships, reducing manufacturing risks. Its focus on reformulating existing drugs supports pharmaceutical companies facing patent expirations.

Five Things You Need to Know

  • Revenue was $20,000 in 2025, unchanged from 2024 (0% growth).
  • Operating expenses fell 15.3% to $516,315 in 2025.
  • Net loss rose 88% to $1,064,034 in 2025.
  • Cash balance was $2,620 at year-end 2025, with a $4.99 million working capital deficit.
  • Only two full-time employees manage all operations and partnerships.

Bottom Line

Skinvisible has evolved by licensing its patented delivery technology and forming strategic partnerships. The company remains focused on niche pharmaceutical and skincare markets, despite ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

2

CEO

Terry H. Howlett

Website

www.skinvisible.com

Headquarters

Las Vegas, NV 89120, US

SKVI Financials

Key Financial Metrics (TTM)

Gross Margin

-1.20%

Operating Margin

-2412.01%

Net Income Margin

-5251.06%

Return on Equity

10.36%

Return on Capital

N/A

Return on Assets

-879.44%

Earnings Yield

-97.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.40M

Volume

1

Avg. Volume

940.742

Financials (TTM)

Gross Profit

-$239.00

Operating Income

-$482.40K

EBITDA

-$457.57K

Operating Cash Flow

-$38.41B

Capital Expenditure

-$1.00

Free Cash Flow

-$38.41B

Cash & ST Invst.

$1.80K

Total Debt

$5.80M

Skinvisible Performance Analysis

Skinvisible annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 279,296-57.9%
20232023-12-31USD 20,000-92.8%
20242024-12-31USD 20,0000.0%
20252025-12-31USD 20,0000.0%
Skinvisible sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Skinvisible annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.2714.2%
20232023-12-31USD -0.5294.5%
20242024-12-31USD -0.11-78.7%
20252025-12-31USD -0.2076.5%
Skinvisible sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-303.1%
Q32025-09-301.6%
Q42025-12-314.4%
Q12026-03-31-3.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$5.00K

+0.0%

Gross Profit

$5.00K

+0.0%

Gross Margin

100.00%

N/A

Market Cap

$1.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$540.40K

N/A

Employees

2

N/A

Net Income

-$267.18K

+4.9%

EBITDA

-$120.93K

+10.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.80K

-86.6%

Total Debt

$5.80M

+0.9%

Accounts Receivable

$22.59K

+25.1%

Inventory

$0.00

N/A

Long Term Debt

$5.37M

+0.0%

Short Term Debt

$423.62K

+14.0%

Return on Assets

-8.79%

N/A

Return on Invested Capital

9.35%

N/A

Free Cash Flow

-$820.00

+97.4%

Operating Cash Flow

-$822.00

+97.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SVINScheid Vineyards Inc.
$0.69+0.00%
DRNKNOHO, Inc.
$0.00+0.00%
IFBCItalian Food & Beverage Corp.
$0.00+17.86%
HRSRHorrison Resources Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About SKVI

What is the current price of Skinvisible?

Skinvisible is trading at $0.20 per share.

What is the 52-week range for Skinvisible?

Over the past 52 weeks, Skinvisible has traded between $0.08 and $0.90.

How much debt does Skinvisible have?

As of the most recent reporting period, Skinvisible reported total debt of $5.80M.

How much cash does Skinvisible have on hand?

Skinvisible reported $1.80K in cash and cash equivalents in its most recent financial results.

What is Skinvisible’s dividend yield?

Skinvisible does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services